KCM
SLRN

Kennedy Capital Management’s ACELYRIN SLRN Stock Holding History

Kennedy Capital Management’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-446,850
Closed -$1.4M – 695
2024
Q4 		$1.4M Sell
446,850
-5,920
-1% -$28.7K 0.03% 561
2024
Q3 		$2.23M Sell
452,770
-69,489
-13% -$359K 0.05% 496
2024
Q2 		$2.3M Buy
522,259
+35,699
+7% +$167K 0.05% 491
2024
Q1 		$3.28M Buy
486,560
+12,554
+3% +$95.4K 0.07% 425
2023
Q4 		$3.54M Buy
+474,006
New +$4.05M 0.08% 374
2023
Q3 		– Sell
-55,719
Closed -$1.16M – 710
2023
Q2 		$1.16M Buy
+55,719
New +$1.14M 0.03% 538

Other funds holding SLRN

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Kennedy Capital Management's SLRN Position: Q1 2025 in Review

Kennedy Capital Management sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 446,850 shares — an estimated $1.4M sold.

Kennedy Capital Management first reported a position in SLRN in Q2 2023 and held it in 6 quarters. The position peaked at $3.54M in Q4 2023. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • Kennedy Capital Management reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 446,850 ACELYRIN shares in Q1 2025, an estimated $1.4M.
  • Kennedy Capital Management first reported a position in ACELYRIN in Q2 2023 and held it in 6 quarters.
  • Kennedy Capital Management's ACELYRIN position peaked at $3.54M in Q4 2023.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on Kennedy Capital Management's 13F filing for Q1 2025, filed 13 May 2025.